Genedrive Plc

Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.

Genedrive Plc trades as GDR.L on LSE. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in GBP.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £764,000 of revenue and -£5.23M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Genedrive Plc can be compared against peers such as ANGLE plc, Chill Brands Group PLC, Cizzle Biotechnology Holdings Plc, Cambridge Nutritional Sciences plc, Feedback plc, GENinCode plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £7.63M, beta of 1.02, and return on equity of -363.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

GDR.L currently shows total debt of £0 and beta of 1.02. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.genedriveplc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.